Skip to main content
. 2012 Nov 6;12:167. doi: 10.1186/1471-2288-12-167

Table 2.

Trial Data: Number of patients N; improvement in HAQ score Δ HAQ; number of ACR20, ACR50, ACR70 responders; HAQ score at baseline HAQbase; + indicates additional treatment with MTX

Trial Arm N ΔHAQ(SD) ACR20 ACR50 ACR70 HAQbase
Weinblatt et al. [31]
 P+
 62
 0.27 (0.6)
 9
 5
 3
 1.64
 
 Ada+
 69
 0.54 (0.6)
 33
 22
 7
 1.52
 
 Ada+
 67
 0.62 (0.6)
 45
 37
 18
 1.55
 
 Ada+
 73
 0.59 (0.5)
 48
 31
 14
 1.55
Keystone et al. [32]
 P+
 200
 0.24 (0.5)
 59
 19
 5
 1.45
 
 Ada+
 207
 0.56 (0.5)
 131
 81
 43
 1.44
 
 Ada+
 212
 0.60 (0.5)
 129
 87
 37
 1.48
Van de Putte et al. [33]
 P
 110
 0.07 (0.5)
 21
 9
 2
 1.88
 
 Ada
 112
 0.39 (0.6)
 44
 23
 11
 1.88
 
 Ada
 106
 0.29 (0.6)
 38
 20
 9
 1.88
 
 Ada
 103
 0.49 (0.5)
 55
 36
 19
 1.84
 
 Ada
 113
 0.38 (0.6)
 52
 25
 14
 1.83
Miyasaka [34]
 P
 87
 -0.1 (0.6)
 12
 5
 1
 1.39
 
 Ada
 87
 0.2 (0.5)
 25
 14
 9
 1.57
 
 Ada
 91
 0.2 (0.6)
 40
 22
 11
 1.64
 
 Ada
 87
 0.4 (0.6)
 44
 28
 13
 1.77
Kim at el. [35]
 P+
 63
 0.2 (0.5)
 23
 9
 5
 1.3
 
 Ada+
 65
 0.5 (0.6)
 40
 28
 14
 1.4
Maini et al. [36]
 P+
 88
 0.3 (0.5)†
 18
 7
 0
 1.8
 
 Inf+
 86
 0.3 (0.5)†
 45
 22
 7
 1.8
 
 Inf+
 86
 0.5 (0.5)†
 47
 25
 9
 1.8
 
 Inf+
 87
 0.5 (0.6)†
 51
 26
 15
 1.8
 
 Inf+
 81
 0.4 (0.5)†
 49
 21
 9
 1.5
Westhoven et al.[37]
 P+
 363
 -
 87
 33
 16
 1.5
 
 Inf+
 360
 -
 199
 110
 48
 1.5
 
 Inf+
 361
 -
 205
 119
 54
 1.5
Zhang et al. [38]
 P+
 86
 0.45 (-)
 42
 22
 12
 1.6
 
 Inf+
 87
 0.76 (-)
 66
 38
 20
 1.6
Schiff et al. [39]
 P+
 110
 -
 49
 22
 10
 1.8
 
 Inf+
 165
 -
 98
 61
 40
 1.7
Moreland et al. [40]
 P
 80
 0.03 (-)
 9
 4
 1
 1.7
 
 Eta
 76
 0.58 (-)
 39
 18
 7
 1.7
 
 Eta
 78
 0.62 (-)
 46
 31
 12
 1.6
Weinblatt et al. [41]
 P+
 30
 0.4 (-)
 8
 1
 0
 1.5
 
 Eta+
 59
 0.7 (-)
 42
 23
 9
 1.5
Keystone et al. [42]
 P+
 133
 0.13red* (0.4)‡
 37
 18
 7
 1.25*
 
 Gol
 133
 0.13* (0.7)‡
 47
 26
 15
 1.38*
 
 Gol+
 89
 0.38* (0.5)‡
 53
 33
 18
 1.38*
 
 Gol+
 89
 0.5* (0.5)‡
 53
 29
 16
 1.38*
Kay et al. [43]
 P+
 35
 -
 13
 2
 0
 1.3
 
 Gol+
 35
 -
 21
 13
 3
 1.7
 
 Gol+
 34
 -
 19
 10
 6
 1.8
Keystone et al. [44]
 P+
 199
 0.18 (-)
 27
 15
 6
 1.7
 
 Cert+
 393
 0.60 (-)
 231
 146
 84
 1.7
 
 Cert+
 390
 0.63 (-)
 237
 156
 79
 1.7
Smolen et al. [45]
 P+
 127
 0.14 (0.5)
 11
 4
 1
 1.6
 
 Cert+
 246
 0.5 (0.5)
 141
 80
 39
 1.6
 
 Cert+
 246
 0.5 (0.5)
 142
 81
 26
 1.6
Fleischmann et al. [46]
 P
 109
 -0.07 (0.4)†
 10
 4
 0
 1.6
  Cert 111 0.39 (0.7)† 51 25 9 1.4

Ada=adalimumab; Inf=infliximab; Eta=etanercept; Gol=golimumab, Cert=certolizumab, P=placebo. *Median; ‡estimated from IQR; †data provided by authors following request.